share_log

D: Filing D

D: Filing D

D：發行公告
美股sec公告 ·  04/25 16:08
Moomoo AI 已提取核心訊息
NeuroSense Therapeutics Ltd., a biotechnology company incorporated in Israel, has successfully completed an exempt offering of securities, raising a total of $4,470,000 USD as reported in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which included options, warrants, or other rights to acquire securities, was conducted under Rule 506(b) of the Securities Act. The date of the first sale was April 15, 2024, and the company intends the offering to last more than one year. NeuroSense Therapeutics has declined to disclose its revenue range or aggregate net asset value. The company has also confirmed that the offering is not connected to a business combination transaction. A placement agent's fee was paid, which included a cash fee and ordinary shares of the company. The total number of investors in the offering was one, and no proceeds from the offering are proposed to be used for payments to executive officers, directors, or promoters. The CEO of NeuroSense Therapeutics, Alon Ben-Noon, signed the filing on April 25, 2024.
NeuroSense Therapeutics Ltd., a biotechnology company incorporated in Israel, has successfully completed an exempt offering of securities, raising a total of $4,470,000 USD as reported in a new Form D notice filed with the U.S. Securities and Exchange Commission (SEC). The offering, which included options, warrants, or other rights to acquire securities, was conducted under Rule 506(b) of the Securities Act. The date of the first sale was April 15, 2024, and the company intends the offering to last more than one year. NeuroSense Therapeutics has declined to disclose its revenue range or aggregate net asset value. The company has also confirmed that the offering is not connected to a business combination transaction. A placement agent's fee was paid, which included a cash fee and ordinary shares of the company. The total number of investors in the offering was one, and no proceeds from the offering are proposed to be used for payments to executive officers, directors, or promoters. The CEO of NeuroSense Therapeutics, Alon Ben-Noon, signed the filing on April 25, 2024.
在以色列註冊的生物技術公司NeuroSense Therapeutics Ltd. 已成功完成證券的豁免發行，根據向美國證券交易委員會（SEC）提交的新Form D通知中所述，共籌集了4470,000美元。此次發行包括期權、認股權證或其他收購證券的權利，是根據《證券法》第506（b）條進行的。首次出售日期爲2024年4月15日，該公司打算此次發行持續一年以上。NeuroSense Therapeutics拒絕透露其收入範圍或總淨資產價值。該公司還證實，此次發行與業務合併交易無關。已支付配售代理費，其中包括現金費和公司的普通股。本次發行的投資者總數爲一人，不建議將此次發行的收益用於向執行官、董事或發起人付款。NeuroSense Therapeutics 首席執行官 Alon Ben-Noon 於 2024 年 4 月 25 日簽署了該文件。
在以色列註冊的生物技術公司NeuroSense Therapeutics Ltd. 已成功完成證券的豁免發行，根據向美國證券交易委員會（SEC）提交的新Form D通知中所述，共籌集了4470,000美元。此次發行包括期權、認股權證或其他收購證券的權利，是根據《證券法》第506（b）條進行的。首次出售日期爲2024年4月15日，該公司打算此次發行持續一年以上。NeuroSense Therapeutics拒絕透露其收入範圍或總淨資產價值。該公司還證實，此次發行與業務合併交易無關。已支付配售代理費，其中包括現金費和公司的普通股。本次發行的投資者總數爲一人，不建議將此次發行的收益用於向執行官、董事或發起人付款。NeuroSense Therapeutics 首席執行官 Alon Ben-Noon 於 2024 年 4 月 25 日簽署了該文件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息